AMG National Trust Bank bought a new stake in Novo Nordisk A/S (NYSE:NVO – Get Rating) during the 3rd quarter, Holdings Channel.com reports. The firm bought 2,241 shares of the company’s stock, valued at approximately $223,000.
Several other institutional investors have also recently bought and sold shares of the company. Cubist Systematic Strategies LLC increased its position in shares of Novo Nordisk A/S by 184.4% during the 2nd quarter. Cubist Systematic Strategies LLC now owns 73,193 shares of the company’s stock worth $8,156,000 after purchasing an additional 47,455 shares during the last quarter. First Horizon Advisors Inc. increased its position in shares of Novo Nordisk A/S by 575.7% during the 2nd quarter. First Horizon Advisors Inc. now owns 3,007 shares of the company’s stock worth $335,000 after purchasing an additional 2,562 shares during the last quarter. Keybank National Association OH increased its position in shares of Novo Nordisk A/S by 11.1% during the 3rd quarter. Keybank National Association OH now owns 27,511 shares of the company’s stock worth $2,741,000 after purchasing an additional 2,755 shares during the last quarter. ARGI Investment Services LLC acquired a new position in shares of Novo Nordisk A/S during the 2nd quarter worth approximately $238,000. Finally, First American Trust FSB increased its position in shares of Novo Nordisk A/S by 4.1% during the 2nd quarter. First American Trust FSB now owns 51,452 shares of the company’s stock worth $5,733,000 after purchasing an additional 2,004 shares during the last quarter. Institutional investors own 6.09% of the company’s stock.
Analysts Set New Price Targets
Several research analysts have weighed in on the company. Cowen boosted their price target on Novo Nordisk A/S from $130.00 to $145.00 in a research report on Monday, December 12th. Barclays boosted their target price on Novo Nordisk A/S from 825.00 to 850.00 and gave the stock an “overweight” rating in a report on Friday, October 14th. Oddo Bhf raised Novo Nordisk A/S from a “neutral” rating to an “outperform” rating in a report on Thursday, September 29th. StockNews.com started coverage on Novo Nordisk A/S in a report on Wednesday, October 12th. They set a “strong-buy” rating on the stock. Finally, Cowen boosted their target price on Novo Nordisk A/S from $130.00 to $145.00 in a report on Monday, December 12th. Two research analysts have rated the stock with a sell rating, four have issued a hold rating, eleven have issued a buy rating and one has issued a strong buy rating to the company’s stock. Based on data from MarketBeat, the company has an average rating of “Moderate Buy” and an average target price of $697.78.
Novo Nordisk A/S Stock Performance
Novo Nordisk A/S (NYSE:NVO – Get Rating) last released its earnings results on Wednesday, November 2nd. The company reported $0.86 earnings per share for the quarter, beating analysts’ consensus estimates of $0.84 by $0.02. The firm had revenue of $6.17 billion during the quarter, compared to the consensus estimate of $6.09 billion. Novo Nordisk A/S had a return on equity of 72.57% and a net margin of 31.57%. On average, equities analysts forecast that Novo Nordisk A/S will post 3.38 EPS for the current year.
Novo Nordisk A/S Profile
Novo Nordisk A/S is a global healthcare company, which engages in the the discovery, development, manufacturing and marketing of pharmaceutical products. It operates through the Diabetes and Obesity Care, and Biopharm segments. The Diabetes and Obesity Care segment includes insulin, GLP-1 and related delivery systems, oral antidiabetic products (OAD), obesity, and other serious chronic diseases.
- Get a free copy of the StockNews.com research report on Novo Nordisk A/S (NVO)
- Pliant Therapeutics Gaps 34% Higher: More Upside To Come?
- How Will Early 2023 Layoffs Affect These 5 Biotech Stocks?
- Is the Pain Over for Baudax Bio Investors after a 70% Spike?
- Will Rocket Lab’s First U.S. Launch Send Stock Into Stratosphere?
- 3 Retail Stocks Ringing the Register in 2023
Receive News & Ratings for Novo Nordisk A/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Novo Nordisk A/S and related companies with MarketBeat.com's FREE daily email newsletter.